Latest news

Thumbnail image for Try a different challenge and make it count!

Try a different challenge and make it count!

Are you carrying out work on behalf of charities?Would you like to do more in this area?If the answer is yes, tell the industry by entering the new, Charity Challenge today.

25th May 2018

Thumbnail image for Enter now and take the next step in your career

Enter now and take the next step in your career

The PharmaTimes Marketer of the Year Awards will return to London in November, alongside Communications Team of the Year and the all-new Sales Awards. Get involved with the 25th anniversary celebrations as this unique competition continues to raise standards, drive innovation and put patient outcomes at the centre of healthcare marketing.

25th May 2018

Thumbnail image for Have you entered the PharmaTimes Sales Awards yet?

Have you entered the PharmaTimes Sales Awards yet?

If not, you should. Now!Dr Jim Golby PhD FCIPD, co-chair of the competition’s executive steering group (ESG) says: "I strongly believe that the newly imagined 2018 Pharma Sales Awards will provide a superb methodology for identifying and recognising the very best sales professionals in our Industry today.”

25th May 2018

Thumbnail image for US clears first enzyme therapy for PKU

US clears first enzyme therapy for PKU

Biomarin’s Palynziq has been approved as the first enzyme therapy to treat the rare brain-threatening genetic disease phenylketonuria (PKU) in adults in the US.

25th May 2018

Thumbnail image for Imbruvica/Gazyva combo improves PFS in CLL patients

Imbruvica/Gazyva combo improves PFS in CLL patients

A combination of AbbVie/Johnson & Johnson’s Imbruvica and Roche’s Gazyva has taken a step closer to becoming first chemotherapy-free CD20 combination for first-line treatment of chronic lymphocytic leukaemia (CLL), after showing promise in a late-stage clinical trial.

25th May 2018

Thumbnail image for NICE issues decision on Mylotarg, Besponsa for leukaemia

NICE issues decision on Mylotarg, Besponsa for leukaemia

The National Institute for Health and Care Excellence has issued draft guidelines backing restricted use of Pfizer’s Mylotarg for newly diagnosed acute myeloid leukaemia (AML), but has asked for more information on the firm’s Besponsa for a type of acute lymphoblastic leukaemia (ALL).

25th May 2018

Previous  --   7 8 9 10 11 12 13 14 15 16   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download